10-Q: LENSAR Inc. Reports Second Quarter 2024 Results, Revenue Up 5% Year-Over-Year

LENSAR Inc. saw a 5% increase in revenue year-over-year for the second quarter of 2024, driven by increased ALLY System sales and procedure volume, despite a net loss of $9.0 million.

Summary

• LENSAR Inc. reported a 5% increase in total revenue for the three months ended June 30, 2024, reaching $12.6 million, compared to $12.0 million in the same period of 2023.
• Product revenue increased by 2% to $9.5 million, primarily due to increased procedure volume, offset by a decrease in system sales.
• Lease revenue rose by 15% to $1.95 million, and service revenue increased by 22% to $1.15 million.
• The company's net loss for the quarter was $9.0 million, which included a $3.7 million impairment charge on intangible assets.
• For the six months ended June 30, 2024, total revenue increased by 15% to $23.2 million, compared to $20.3 million in the same period of 2023.
• The net loss for the six-month period was $11.2 million, which also included the $3.7 million impairment charge.
• The company's installed base of systems is approximately 330 as of June 30, 2024.
• Approximately 79% and 84% of revenue was attributable to recurring sources for the three and six months ended June 30, 2024, respectively.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While revenue is growing, the company is still experiencing significant losses and faces numerous risks. The impairment charge and potential need for further capital raises are concerning, but the growth in recurring revenue and the ALLY System launch are positive signs. Overall, the sentiment is neutral to slightly negative.

Positives

• The company experienced a 5% increase in total revenue for the three months ended June 30, 2024, indicating growth in sales.
• Lease revenue increased by 15% and service revenue increased by 22% for the three months ended June 30, 2024, showing strong performance in these areas.
• The company's installed base of systems is approximately 330 as of June 30, 2024, indicating a growing customer base.
• Recurring revenue sources accounted for 79% and 84% of total revenue for the three and six months ended June 30, 2024, respectively, providing a stable revenue stream.

Negatives

• The company reported a net loss of $9.0 million for the three months ended June 30, 2024, indicating ongoing financial challenges.
• The net loss included a $3.7 million impairment charge on intangible assets, which negatively impacted profitability.
• The company's cost of revenue increased by 11% for the three months ended June 30, 2024, outpacing the revenue increase.
• The company has an accumulated deficit of $123.1 million as of June 30, 2024, indicating a history of losses.

Risks

• The company's results are subject to economic uncertainty and potential deteriorations in economic conditions.
• The company expects to incur operating losses for the near-term future and cannot assure profitability.
• The commercial success of the ALLY System depends on regulatory clearances and market acceptance.
• Patients may not be willing to pay the price difference for advanced cataract procedures.
• The company's future capital needs are uncertain, and additional funds may not be available on acceptable terms.
• Supply chain disruptions and price increases may adversely affect the company's ability to manufacture products.
• The company faces competition from companies with longer operating histories and greater resources.
• The company is subject to extensive government regulation and oversight.
• The company's success depends on its ability to obtain, maintain, and protect its intellectual property rights.
• The company is exposed to the credit risk of some of its customers, which could result in material losses.
• The company may be unable to accurately forecast customer demand and its inventory levels.
• Failure to secure adequate coverage or reimbursement by third-party payors could impact revenue and growth.
• Product liability suits could cause the company to incur substantial liabilities.
• The company's financial results may fluctuate significantly and may not fully reflect the underlying performance of the business.
• The company may be unable to manage its anticipated growth effectively.
• The company relies significantly on the use of information technology and is subject to cybersecurity risks.
• The company is subject to certain federal, state and foreign laws pertaining to healthcare fraud and abuse, including anti-kickback, self-referral, false claims and fraud laws.
• The company is subject to anti-corruption, anti-bribery and similar laws and any violations by us of such laws could result in fines or other penalties.
• The company is subject to continuing contingent liabilities of PDL BioPharma, Inc. following the Spin-Off.

Future Outlook

The company expects annual revenue and selling, general and administrative expenses to increase from current levels associated with the increase in ALLY System placements. The company's growth depends in part on its ability to produce the ALLY System in sufficient quantities, within requested timelines and at an acceptable price to satisfy customer demand. The company may need to raise additional capital through equity or debt financings, borrowings under credit facilities or from other sources in the future.

Management Comments

• Management believes the Company's cash and cash equivalents on hand, together with cash generated from the future sale and lease of products, will provide sufficient funds for its operating, investing, and financing cash flows for a period of at least twelve months from the date of issuance of these financial statements.
• The Company expects annual revenue and selling, general and administrative expenses to increase from current levels associated with the increase in ALLY System placements.
• The Company's liquidity needs will be largely determined by the Company's ability to successfully commercialize its products and the progression, additional regulatory clearances or certifications and launch of the ALLY System in additional jurisdictions in the future.

Industry Context

The medical device market in which LENSAR participates is highly competitive and technology-driven. The company faces competition from large multinational medical device companies, as well as smaller, emerging players focused on product innovation. The company's growth and market presence depend on the adoption and acceptance of its products by surgeons and healthcare facilities, as well as the availability of coverage and reimbursement for procedures using its systems.

Comparison to Industry Standards

• LENSAR competes with established players like Alcon, Bausch + Lomb, Johnson & Johnson, Carl Zeiss AG, Zeimer, and KERANOVA S.A., all of which have longer operating histories and greater resources.
• Unlike some competitors, LENSAR does not have its own intraocular lens (IOL), which could be a competitive disadvantage.
• The company's reliance on a network of independent distributors for international sales is a common practice in the medical device industry, but it also exposes the company to risks associated with distributor performance and relationships.
• The company's focus on continuous innovation and the launch of the ALLY System is consistent with industry trends towards advanced technologies in cataract surgery.
• The company's financial performance, including revenue growth and net losses, is comparable to other emerging medical device companies in the growth phase.

Legal Proceedings

• Stockholders Ryan Schaper and Christopher P. Bolster filed a Verified Amended Class Action Complaint against the Company and certain of its officers and members of the board of directors, alleging violations of Sections 14(a) and 20(a) of the Exchange Act, as well as Rule 14d-9 promulgated thereunder, and asserting claims challenging the adequacy of disclosures in the definitive proxy statement filed with the SEC on June 20, 2023, in connection with the Private Placement.

Related Party Transactions

• In May 2023, the Company completed the Private Placement with NR-GRI Partners, LP, an affiliate of North Run Capital, LP.
• In June 2023, the Company entered into an international distribution agreement in India with a company owned by an employee at that time. The related party relationship ended on April 1, 2024.

Stakeholder Impact

• Shareholders face the risk of potential dilution from future equity offerings and the possibility of continued losses.
• Employees may experience changes in compensation and benefits as the company manages its growth and financial performance.
• Customers may benefit from the company's continued innovation and product development, but may also face price increases due to inflationary pressures.
• Suppliers may experience changes in demand and pricing as the company manages its supply chain.
• Creditors face the risk of potential defaults if the company's financial performance does not improve.

Next Steps

• The company will continue to expand its commercial infrastructure and further commercialize the ALLY System.
• The company will pursue further regulatory clearances of the ALLY System in additional jurisdictions.
• The company will continue to monitor and address supply chain issues and inflationary pressures.
• The company will continue to evaluate its capital needs and may seek additional funding through various means.

Key Dates

Keywords

LENSAR, ALLY System, cataract surgery, medical devices, laser system, ophthalmology, revenue, financial results, regulatory approvals, intellectual property